Monkeypox Testings Market Report: 2025-2033 Growth Analysis

The global monkeypox testing sector remains a niche but strategically important diagnostic category. Base-year revenue of $2.28 million in 2025 reflects sustained demand from public health surveillance, hospital infection control, and reference laboratory networks. At a 4.3% CAGR, the market is projected to reach $3.19 million by 2033, with growth concentrated in molecular platforms and automated sample-to-answer systems. The PCR Monkeypox Test Kits Market contributes the largest share, supported by high analytical sensitivity and regulatory acceptance in outbreak response. The Lateral Flow Monkeypox Assay Market remains smaller but gains traction in decentralized settings where rapid triage is required.

Regional momentum is uneven. North America accounts for 38% of global value, driven by CDC-funded laboratory capacity, FDA emergency use authorizations, and high-complexity CLIA labs. Europe follows with 27%, where IVDR compliance shapes product validation and post-market surveillance. Asia-Pacific represents 22%, with China, Japan, and India expanding molecular diagnostic infrastructure. South America and Middle East & Africa together hold 13%, but public health procurement and outbreak preparedness programs are creating incremental demand.

Macro drivers include enduring mpox endemicity, expanded wastewater surveillance, and clinician familiarity with orthopoxvirus testing. Restraints include declining outbreak-driven volumes after the 2022 global emergency, reimbursement ambiguity, and high reagent costs relative to test volumes. The Monkeypox Diagnostic Reagents Market is also shaped by supply chain concentration in synthetic oligonucleotides and monoclonal antibodies.

Key strategic takeaways:

• PCR remains the revenue anchor, representing 58% of market value and the most defensible margin profile.
• Lateral flow assays are forecast to grow at 3.9% CAGR, driven by point-of-care and low-resource deployments.
• Public health laboratories and Diagnostic Laboratories Testing Market buyers prioritize regulatory clearance, sensitivity thresholds, and lot-to-lot reproducibility over unit price.
• North America and Europe will continue to set compliance benchmarks, while Asia-Pacific offers the fastest incremental volume growth.

Segment Analysis Matrix

PCR-based mpox testing generates an estimated $1.32 million in 2025, equal to 58% of total market value. The PCR Monkeypox Test Kits Market benefits from entrenched laboratory workflows, CDC orthopoxvirus assay protocols, and regulatory acceptance across FDA, EMA, and WHO frameworks. Real-time PCR and multiplex panels that differentiate mpox from varicella and other rash illnesses command premium pricing. Automated extraction and master mix formats reduce hands-on time and improve throughput in hospital and public health laboratories.

The Lateral Flow Monkeypox Assay Market serves decentralized testing, including sexual health clinics, travel medicine sites, and community outbreak units. Although sensitivity is lower than PCR, LFA formats support faster clinical decisions when lab access is constrained. Growth is tied to antigen target optimization and thermostable reagent development. Point-of-care adoption is also influencing the broader Point-of-Care Testing Market, where sample-to-answer simplicity and connectivity features are becoming procurement criteria.

• Multiplex PCR panels are gaining share because they test for mpox, varicella-zoster, and herpes simplex in a single run, improving lab economics.
• Serology and sequencing remain niche but support outbreak investigation and vaccine response monitoring.
• Margin pressure comes from reagent price erosion, high validation costs, and low test volumes outside outbreak periods.
• The Monkeypox Diagnostic Reagents Market faces concentrated supply of enzymes, probes, and synthetic DNA, which limits price competition.
• Reimbursement for mpox testing varies by payer and jurisdiction, creating uncertainty for hospitals and clinics.

Market Dynamics Impact Analysis

Quantitative evaluation shows that public health funding adds an estimated 1.2 percentage points to annual growth during outbreak preparedness cycles. Conversely, a 10% drop in outbreak-related tests can reduce market revenue by approximately $0.18 million because fixed validation costs are spread over fewer units. The 2022 global mpox emergency created a temporary spike, but 2025 demand is structurally lower and more reliant on endemic surveillance, travel medicine, and sexual health screening.

Growth catalysts include wastewater surveillance programs that detect mpox DNA before clinical cases appear. Regulatory developments such as FDA emergency use authorization templates and WHO target product profiles shorten development cycles for new PCR and LFA products. However, these catalysts are partially offset by declining government stockpile purchases and limited commercial payer coverage. The net effect is moderate but durable expansion at 4.3% CAGR, with PCR and automated molecular platforms capturing most incremental value.

Vendor Benchmarking Matrix

• QIAGEN: Supplies PCR workflows and automated sample prep used by public health laboratories; its quarantine and surveillance portfolio supports orthopoxvirus testing.
• Thermo Fisher Scientific: Offers molecular diagnostics instruments and reagents that enable high-throughput mpox PCR within the In Vitro Diagnostics Market.
• Laboratory Corp. of America Holdings: Operates a national reference network that can scale mpox testing during outbreaks and provides payer-contracted access.
• Quest Diagnostics Inc.: Leverages physician ordering and logistics to deliver mpox PCR and serology testing across inpatient and outpatient channels.
• Mayo Clinic Laboratories: Provides high-complexity confirmatory testing and consultative support for unusual rash illness cases.
• Sonic Healthcare Ltd.: Uses international lab operations to serve public health contracts and hospital outreach in multiple regions.
• BD: Focuses on specimen collection, transport, and diagnostic workflow integration, reducing pre-analytical errors.
• Chembio Diagnostics, Inc.: Develops lateral flow formats suited to rapid triage, though regulatory clearance and sensitivity claims remain critical.
• Aegis Sciences Corp.: Combines specialty testing with employer and public health contracts, supporting outbreak screening programs.
• Sonora Quest Laboratories: Delivers regional laboratory access and physician education, particularly in areas with seasonal mpox awareness.

Latest Strategic Moves

• May 2023: QIAGEN expanded its PCR portfolio, improving reagent availability for reference laboratories during residual outbreak activity.
• August 2023: Thermo Fisher Scientific worked with public health laboratories to standardize molecular workflows and reduce validation timelines.
• February 2024: Laboratory Corp. of America Holdings acquired regional lab capacity, strengthening its position in the Diagnostic Laboratories Testing Market.
• September 2024: Quest Diagnostics Inc. integrated mpox PCR into its national menu, increasing physician access and payer billing pathways.
• January 2025: BD advanced specimen collection partnerships, addressing pre-analytical bottlenecks that affect test accuracy and turnaround time.

Regional Growth Comparison

North America remains the most mature market, with 38% of global revenue. Its growth is supported by high-complexity laboratories, CDC orthopoxvirus protocols, and commercial payer coverage for medically necessary testing. The Hospitals & Clinics Testing Market in the United States is shaped by infection prevention requirements, while the Diagnostic Laboratories Testing Market benefits from centralized reference testing.

Europe is the second-largest region, with 27% share. IVDR compliance raises the evidence bar for PCR and LFA manufacturers, but it also consolidates demand toward certified vendors. Germany, France, and the United Kingdom account for most regional value. Asia-Pacific is the fastest-growing region at 4.8% CAGR, led by China, Japan, India, and South Korea. Government-funded molecular laboratory expansion and travel-related surveillance drive incremental demand.

LAMEA holds 13% combined share. South America and Middle East & Africa depend on public health budgets, donor funding, and WHO technical support. Regulatory stringency is lower, but procurement is often centralized and price-sensitive. Across all regions, the Medical Diagnostic Reagents Market and local distribution partnerships determine how quickly testing capacity can scale during outbreaks.

Funding and Deal Snapshot

M&A activity has focused on reference laboratories and molecular diagnostic platform companies. Strategic acquirers seek scalable PCR workflows, regulatory clearances, and access to public health contracts. Private equity interest is more selective because monkeypox testing alone is a small revenue pool; investors prefer platforms that also address sexually transmitted infections, respiratory viruses, and antimicrobial resistance. The Point-of-Care Testing Market has attracted venture funding for rapid antigen and molecular devices that can be repurposed across outbreak pathogens.

High-growth sub-segments include multiplex PCR panels, automated sample-to-answer systems, and wastewater surveillance reagents. Strategic partnerships between assay developers and laboratory networks reduce validation costs and accelerate emergency use authorization submissions. However, funding remains cyclical and tied to outbreak news. The 2022 global emergency triggered a surge, while 2024–2025 investment is more disciplined and focused on endemic surveillance and platform reuse.

Buyer Behavior Matrix

The Hospitals & Clinics Testing Market prioritizes rapid results for patients presenting with rash illness. Hospital buyers often require FDA-cleared or EUA-authorized assays, CLIA-complexity alignment, and integration with electronic medical records. Price elasticity is moderate because testing volumes are low and clinical decisions are urgent. The Diagnostic Laboratories Testing Market is less price-sensitive for high-complexity PCR, where sensitivity and reimbursement matter more than unit cost.

Procurement channels differ by segment. Public health laboratories rely on government tenders and CDC or WHO procurement frameworks. Hospital networks use group purchasing organizations to negotiate reagent pricing and instrument service contracts. Commercial reference laboratories often execute direct agreements with manufacturers to secure supply continuity. Digital purchasing habits have increased since 2020, with electronic catalogs, online ordering portals, and automated inventory alerts becoming standard. Buyers now expect lot traceability, cold-chain documentation, and technical support as part of the Medical Diagnostic Reagents Market offering.

• 1. Technology Type
  • 1.1. Polymerase Chain Reaction (PCR)
  • 1.2. Lateral Flow Assay (LFA)
  • 1.3. Others
• 2. End-use Type
  • 2.1. Hospitals & Clinics
  • 2.2. Diagnostic Laboratories
  • 2.3. Others

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific